A new publication referencing exenatide appeared on September 4, 2026, in the journal Diabetes Technology & Therapeutics. The paper, titled "Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review," is listed as a narrative review. It addresses adjunctive treatment options for patients with type 1 diabetes who use automated insulin delivery, or AID, systems.
Exenatide is an approved compound named in connection with this review. No specific findings, outcomes, or data points from the review have been disclosed beyond its title and publication details. The review's classification as a narrative format means it compiles existing literature on the topic rather than presenting new original trial results, according to the information provided.
This entry is being tracked as a publication event under the identifier 42695140 in the referenced journal. No additional details about study design, patient populations, or conclusions have been made available at this time. Readers interested in this topic should consult the original journal listing for the complete review content once accessible.
For more background on this compound, see the exenatide overview page.